RP @archbiopartners.com: 📚 Nature Reviews: Nephrology (doi.org/10.1038/s41581-024-00820-6): CKD affects more than 800M people globally, steep increase for 2030. Arch is a kidney therapeutics company with a CKD platform and two ongoing Phase II AKI trial…
📚 Nature Reviews: Nephrology (doi.org/10.1038/s41581-024-00820-6): CKD affects more than 800M people globally, steep increase for 2030. Arch is a kidney therapeutics company with a CKD platform and two ongoing Phase II AKI trials. 🔬 archbiopartners.co…
RP @natrevneph.nature.com: We look forward to better integration of kidney disease into the NCD global public health agenda and hope that it will be recognized as a key driver of premature mortality, alongside cardiovascular disease, diabetes, cancer, c…
We look forward to better integration of kidney disease into the NCD global public health agenda and hope that it will be recognized as a key driver of premature mortality, alongside cardiovascular disease, diabetes, cancer, chronic lung disease and men…